FDA RMAT Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as 1L Consolidation Therapy for LBCL August 5, 2026
First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell NHL July 28, 2026
FAILED TRIAL: Ph 3 EPCORE® DLBCL-1 Trial of Epcoritamab in Patients with R/R DLBCL failed to meet primary OS endpoint July 28, 2026
Ph 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with indolent NHL in the watch-and-wait setting July 28, 2026
Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers July 15, 2026
Positive Ph 3 Results for Epcoritamab + Lenalidomide in R/R DLBCL Patients Demonstrated Statistically Significant PFS Improvement July 7, 2026
TEPKINLY (epcoritamab) in Combination with Lenalidomide & Rituximab Approved by the European Commission for the Treatment of R/R Follicular Lymphoma July 7, 2026
Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities Announced June 30, 2026
Japan Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of R/R DLBCL Announced June 23, 2026
FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat indolent non-Hodgkin lymphoma June 2, 2026
Opdivo in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma June 2, 2026
Positive 12-Month Follow-Up Data from Ph 2b CLOVER WaM Study Shows Durable Responses & Efficacy of Iopofosine I 131 in R/R Waldenström Macroglobulinemia May 12, 2026
DMC recommends halting Ph 3 FLASH2 trial of HyBryt (Synthetic Hypericin) in the treatment of CTCL patients post interim efficacy analysis May 6, 2026
Journal of Clinical Oncology Publishes Final Results of Duvelisib PRIMO Ph 2 Trial in R/R Peripheral T-cell Lymphoma May 6, 2026
Wugen Selected for US FDA CMC Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel April 15, 2026
